Treatment of Parkinsonian syndrome with dexetimide.
In an open study, 60 Parkinson patients with varying aetiology were submitted to a treatment with the long-acting antiparkinsonian drug dexetimide and L-Dopa. Rigor, tremor and akinesia were favourably influenced. An advantage over other antiparkinsonian agents is its long duration of action and the possibility of a simple dosage. Further investigations concerning its long-term effect and elucidation of its interactions with different drugs commonly administered in parkinsonian disorders seem desirable.
D000328:Adult; D000368:Aged; D055598:Chemical Phenomena; D002621:Chemistry; D003909:Dexetimide / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010880:Piperidines / Q000008:administration & dosage*
D010880:Piperidines; D003909:Dexetimide; D007980:Levodopa